Covidien delays intranasal insulin spray launch until 2020

Written by by By By “Bloomberg News” contributor the) Most Popular Editors’ pick: Originally published Oct. 13. Covidien’s widely anticipated launch of a nasal spray version of its popular intranasal insulin spray is gaining…

Covidien delays intranasal insulin spray launch until 2020

Written by by By By “Bloomberg News” contributor the) Most Popular

Editors’ pick: Originally published Oct. 13.

Covidien’s widely anticipated launch of a nasal spray version of its popular intranasal insulin spray is gaining steam.

Covidien, a Dublin-based medical device company, had previously said the spray was in final-stage testing and would arrive in the spring, suggesting a July 1, 2020, target. But the company on Oct. 8 postponed the launch until 2020, according to an e-mailed statement from spokeswoman Jackie Berman.

The delayed roll-out was not the result of any major new business problems, Berman said. Rather, Covidien faced supply constraints on the ingredient that is used in the spray, and the product’s regulatory approval was delayed by additional work on its labeling, she said.

“We think the process is on track to the original goal of 2020. We continue to work with regulators to ensure that the proper labeling is in place,” Berman said.

The nasal spray will be the sixth version of CVS’s Adrigo strip, which is the most commonly used insulin spray in the U.S. It’s also used in Europe and Canada.

Contacts: Christina Ryan, [email protected]; Laurence Cazalot, ochrinc(at)covidien.com

Leave a Comment